Current drug discovery strategies against arenavirus infections

References

• Emonet SF, de la Torre JC, Domingo E, Sevilla N. Arenavirus genetic diversity and its biological implications. Infect. Genet. Evol. 9(4), 417–429 (2009).
   PubMed Web of Science ®Google Scholar
• Buchmeier MJ, de la Torre JC, Peters CJ. Arenaviridae: the viruses and their replication. In: Fields Virology. Knipe DL, Howley PM (Eds). Lippincott-Raven, PA, USA, 1791–1828 (2007).
   Google Scholar
• McCormick JB, Fisher-Hoch SP. Lassa fever. Curr. Top. Microbiol. Immunol. 262, 75–109 (2002).
   PubMed Web of Science ®Google Scholar
• Peters CJ. Human infection with arenaviruses in the Americas. Curr. Top. Microbiol. Immunol. 262, 65–74 (2002).
   PubMed Web of Science ®Google Scholar
• Charrel RN, de Lamballerie X, Emonet S. Phylogeny of the genus Arenavirus. Curr. Opin. Microbiol. 11(4), 362–368 (2008).
   PubMed Web of Science ®Google Scholar
• Kunz S, de la Torre JC. Arenavirus infection in the nervous system: uncovering principles of virus-host interaction and viral pathogenesis. In: Neurotropic Viral Infections. Reiss CS (Ed.). Cambridge University Press, Cambridge, UK, 75–93 (2008).
   Google Scholar
• Bonthius DJ, Nichols B, Harb H, Mahoney J, Karacay B. Lymphocytic choriomeningitis virus infection of the developing brain: critical role of host age. Ann. Neurol. 62(4), 356–374 (2007).
   PubMedGoogle Scholar
• Bonthius DJ, Perlman S. Congenital viral infections of the brain: lessons learned from lymphocytic choriomeningitis virus in the neonatal rat. PLoS Pathog. 3(11), e149 (2007).
   Google Scholar
• Fischer SA, Graham MB, Kuehnert MJ et al.; LCMV in Transplant Recipients Investigation Team. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N. Engl. J. Med. 354(21), 2235–2249 (2006).
   PubMed Web of Science ®Google Scholar
• Palacios G, Druce J, Du L et al. A new arenavirus in a cluster of fatal transplant-associated diseases. N. Engl. J. Med. 358(10), 991–998 (2008).
   PubMed Web of Science ®Google Scholar
• McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES. A prospective study of the epidemiology and ecology of Lassa fever. J. Infect. Dis. 155(3), 437–444 (1987).
   PubMed Web of Science ®Google Scholar
• Richmond JK, Baglole DJ. Lassa fever: epidemiology, clinical features, and social consequences. BMJ 327(7426), 1271–1275 (2003).
   PubMed Web of Science ®Google Scholar
• Briese T, Paweska JT, McMullan LK et al. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog. 5(5), e1000455 (2009).
   PubMed Web of Science ®Google Scholar
• Delgado S, Erickson BR, Agudo R et al. Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog. 4(4), e1000047 (2008).
   PubMed Web of Science ®Google Scholar
• Gómez RM, Jaquenod de Giusti C, Sanchez Vallduvi MM, Frik J, Ferrer MF, Schattner M. Junín virus. A XXI century update. Microbes Infect. 13(4), 303–311 (2011).
   PubMedGoogle Scholar
• Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat. Med. 10(12 Suppl.), S110–S121 (2004).
   PubMed Web of Science ®Google Scholar
• de la Torre JC. Molecular and cell biology of the prototypic arenavirus LCMV: implications for understanding and combating hemorrhagic fever arenaviruses. Ann. NY Acad. Sci. 1171(Suppl. 1), E57–E64 (2009).
   Google Scholar
• Meyer BJ, de La Torre JC, Southern PJ. Arenaviruses: Genomic RNAs, Transcription, and Replication. In: Arenaviruses I. Oldstone MB (Ed.). Springer-Verlag, Berlin Heidelberg, Germany, 139–149 (2002).
   Google Scholar
• Lenz O, ter Meulen J, Klenk HD, Seidah NG, Garten W. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc. Natl Acad. Sci. USA 98(22), 12701–12705 (2001).
   PubMed Web of Science ®Google Scholar
• Rojek JM, Lee AM, Nguyen N, Spiropoulou CF, Kunz S. Site 1 protease is required for proteolytic processing of the glycoproteins of the South American hemorrhagic fever viruses Junin, Machupo, and Guanarito. J. Virol. 82(12), 6045–6051 (2008).
   PubMed Web of Science ®Google Scholar
• Beyer WR, Pöpplau D, Garten W, von Laer D, Lenz O. Endoproteolytic processing of the lymphocytic choriomeningitis virus glycoprotein by the subtilase SKI-1/S1P. J. Virol. 77(5), 2866–2872 (2003).
   PubMed Web of Science ®Google Scholar
• Borrow P, Oldstone MB. Characterization of lymphocytic choriomeningitis virus-binding protein(s): a candidate cellular receptor for the virus. J. Virol. 66(12), 7270–7281 (1992).
   PubMed Web of Science ®Google Scholar
• Eschli B, Quirin K, Wepf A, Weber J, Zinkernagel R, Hengartner H. Identification of an N-terminal trimeric coiled-coil core within arenavirus glycoprotein 2 permits assignment to class I viral fusion proteins. J. Virol. 80(12), 5897–5907 (2006).
   PubMed Web of Science ®Google Scholar
• Igonet S, Vaney MC, Vonhrein C et al. X-ray structure of the arenavirus glycoprotein GP2 in its postfusion hairpin conformation. Proc. Natl Acad. Sci. USA 108(50), 19967–19972 (2011).
   PubMedGoogle Scholar
• Eichler R, Lenz O, Strecker T, Eickmann M, Klenk HD, Garten W. Identification of Lassa virus glycoprotein signal peptide as a trans-acting maturation factor. EMBO Rep. 4(11), 1084–1088 (2003).
   PubMed Web of Science ®Google Scholar
• Eichler R, Lenz O, Strecker T, Garten W. Signal peptide of Lassa virus glycoprotein GP-C exhibits an unusual length. FEBS Lett. 538(1-3), 203–206 (2003).
   PubMed Web of Science ®Google Scholar
• Froeschke M, Basler M, Groettrup M, Dobberstein B. Long-lived signal peptide of lymphocytic choriomeningitis virus glycoprotein pGP-C. J. Biol. Chem. 278(43), 41914–41920 (2003).
   PubMed Web of Science ®Google Scholar
• York J, Romanowski V, Lu M, Nunberg JH. The signal peptide of the Junín arenavirus envelope glycoprotein is myristoylated and forms an essential subunit of the mature G1–G2 complex. J. Virol. 78(19), 10783–10792 (2004).
   PubMed Web of Science ®Google Scholar
• Agnihothram SS, York J, Trahey M, Nunberg JH. Bitopic membrane topology of the stable signal peptide in the tripartite Junín virus GP-C envelope glycoprotein complex. J. Virol. 81(8), 4331–4337 (2007).
   PubMedGoogle Scholar
• Agnihothram SS, York J, Nunberg JH. Role of the stable signal peptide and cytoplasmic domain of G2 in regulating intracellular transport of the Junín virus envelope glycoprotein complex. J. Virol. 80(11), 5189–5198 (2006).
   PubMed Web of Science ®Google Scholar
• York J, Nunberg JH. A novel zinc-binding domain is essential for formation of the functional junin virus envelope glycoprotein complex. J. Virol. 10, 10 (2007).
   Google Scholar
• Briknarová K, Thomas CJ, York J, Nunberg JH. Structure of a zinc-binding domain in the Junin virus envelope glycoprotein. J. Biol. Chem. 286(2), 1528–1536 (2011).
   PubMedGoogle Scholar
• Eichler R, Strecker T, Kolesnikova L et al. Characterization of the Lassa virus matrix protein Z: electron microscopic study of virus-like particles and interaction with the nucleoprotein (NP). Virus Res. 100(2), 249–255 (2004).
   PubMed Web of Science ®Google Scholar
• York J, Nunberg JH. Role of the stable signal peptide of Junín arenavirus envelope glycoprotein in pH-dependent membrane fusion. J. Virol. 80(15), 7775–7780 (2006).
   PubMed Web of Science ®Google Scholar
• Cao W, Henry MD, Borrow P et al. Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 282(5396), 2079–2081 (1998).
   PubMed Web of Science ®Google Scholar
• Oldstone MB, Campbell KP. Decoding arenavirus pathogenesis: essential roles for alpha-dystroglycan-virus interactions and the immune response. Virology 411(2), 170–179 (2011).
   PubMedGoogle Scholar
• Shimojima M, Ströher U, Ebihara H, Feldmann H, Kawaoka Y. Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry. J. Virol. 86(4), 2067–2078 (2012).
   PubMedGoogle Scholar
• Radoshitzky SR, Abraham J, Spiropoulou CF et al. Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature 446(7131), 92–96 (2007).
   PubMed Web of Science ®Google Scholar
• Radoshitzky SR, Kuhn JH, Spiropoulou CF et al. Receptor determinants of zoonotic transmission of New World hemorrhagic fever arenaviruses. Proc. Natl Acad. Sci. USA 105(7), 2664–2669 (2008).
   PubMed Web of Science ®Google Scholar
• Spiropoulou CF, Kunz S, Rollin PE, Campbell KP, Oldstone MB. New World arenavirus clade C, but not clade A and B viruses, utilizes alpha-dystroglycan as its major receptor. J. Virol. 76(10), 5140–5146 (2002).
   PubMedGoogle Scholar
• Martinez MG, Cordo SM, Candurra NA. Characterization of Junin arenavirus cell entry. J. Gen. Virol. 88(Pt 6), 1776–1784 (2007).
   PubMed Web of Science ®Google Scholar
• Quirin K, Eschli B, Scheu I, Poort L, Kartenbeck J, Helenius A. Lymphocytic choriomeningitis virus uses a novel endocytic pathway for infectious entry via late endosomes. Virology 378(1), 21–33 (2008).
   PubMed Web of Science ®Google Scholar
• Rojek JM, Perez M, Kunz S. Cellular entry of lymphocytic choriomeningitis virus. J. Virol. 82(3), 1505–1517 (2008).
   PubMed Web of Science ®Google Scholar
• Rojek JM, Sanchez AB, Nguyen NT, de la Torre JC, Kunz S. Different mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses. J. Virol. 82(15), 7677–7687 (2008).
   PubMed Web of Science ®Google Scholar
• Pasqual G, Rojek JM, Masin M, Chatton JY, Kunz S. Old World arenaviruses enter the host cell via the multivesicular body and depend on the endosomal sorting complex required for transport. PLoS Pathog. 7(9), e1002232 (2011).
   PubMedGoogle Scholar
• Nunberg JH, York J. The curious case of arenavirus entry, and its inhibition. Viruses 4(1), 83–101 (2012).
   PubMedGoogle Scholar
• Urata S, de la Torre JC. Arenavirus budding. Adv. Virol. 2011, 180326 (2011).
   PubMedGoogle Scholar
• Perez M, Craven RC, de la Torre JC. The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc. Natl Acad. Sci. USA 100(22), 12978–12983 (2003).
   PubMed Web of Science ®Google Scholar
• Strecker T, Eichler R, Meulen J et al. Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles [corrected]. J. Virol. 77(19), 10700–10705 (2003).
   PubMed Web of Science ®Google Scholar
• Urata S, Noda T, Kawaoka Y, Yokosawa H, Yasuda J. Cellular factors required for Lassa virus budding. J. Virol. 80(8), 4191–4195 (2006).
   PubMed Web of Science ®Google Scholar
• Capul AA, Perez M, Burke E, Kunz S, Buchmeier MJ, de la Torre JC. Arenavirus Z-glycoprotein association requires Z myristoylation but not functional RING or late domains. J. Virol. 81(17), 9451–9460 (2007).
   PubMed Web of Science ®Google Scholar
• Emonet SE, Urata S, de la Torre JC. Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategies. Virology 411(2), 416–425 (2011).
   PubMed Web of Science ®Google Scholar
• Sánchez AB, de la Torre JC. Rescue of the prototypic arenavirus LCMV entirely from plasmid. Virology 350(2), 370–380 (2006).
   PubMed Web of Science ®Google Scholar
• de la Torre JC. Reverse genetics approaches to combat pathogenic arenaviruses. Antiviral. Res. 80(3), 239–250 (2008).
   PubMedGoogle Scholar
• Albariño CG, Bergeron E, Erickson BR, Khristova ML, Rollin PE, Nichol ST. Efficient reverse genetics generation of infectious junin viruses differing in glycoprotein processing. J. Virol. 83(11), 5606–5614 (2009).
   PubMed Web of Science ®Google Scholar
• Emonet SF, Seregin AV, Yun NE et al. Rescue from cloned cDNAs and in vivo characterization of recombinant pathogenic Romero and live-attenuated Candid #1 strains of Junin virus, the causative agent of Argentine hemorrhagic fever disease. J. Virol. 85(4), 1473–1483 (2011).
   PubMed Web of Science ®Google Scholar
• Carnec X, Baize S, Reynard S et al. Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophages. J. Virol. 85(22), 12093–12097 (2011).
   PubMed Web of Science ®Google Scholar
• Emonet SF, Garidou L, McGavern DB, de la Torre JC. Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. Proc. Natl Acad. Sci. USA 106(9), 3473–3478 (2009).
   PubMed Web of Science ®Google Scholar
• Gibson RM, Arts EJ. Past, present, and future of entry inhibitors as HIV microbicides. Curr. HIV Res. 10(1), 19–26 (2012).
   PubMedGoogle Scholar
• Mercorelli B, Lembo D, Palù G, Loregian A. Early inhibitors of human cytomegalovirus: state-of-art and therapeutic perspectives. Pharmacol. Ther. 131(3), 309–329 (2011).
   PubMedGoogle Scholar
• Schmidt AG, Lee K, Yang PL, Harrison SC. Small-molecule inhibitors of dengue-virus entry. PLoS Pathog. 8(4), e1002627 (2012).
   PubMed Web of Science ®Google Scholar
• Côté M, Misasi J, Ren T et al. Small-molecule inhibitors reveal Niemann–Pick C1 is essential for Ebola virus infection. Nature 477(7364), 344–348 (2011).
   PubMed Web of Science ®Google Scholar
• Murineddu G, Murruzzu C, Pinna GA. An overview on different classes of viral entry and respiratory syncitial virus (RSV) fusion inhibitors. Curr. Med. Chem. 17(11), 1067–1091 (2010).
   PubMedGoogle Scholar
• Abraham J, Corbett KD, Farzan M, Choe H, Harrison SC. Structural basis for receptor recognition by New World hemorrhagic fever arenaviruses. Nat. Struct. Mol. Biol. 17(4), 438–444 (2010).
   PubMed Web of Science ®Google Scholar
• Helguera G, Jemielity S, Abraham J et al. An antibody recognizing the apical domain of human transferrin receptor 1 efficiently inhibits the entry of all New World hemorrhagic fever arenaviruses. J. Virol. 86(7), 4024–4028 (2012).
   PubMed Web of Science ®Google Scholar
• Kunz S. Receptor binding and cell entry of Old World arenaviruses reveal novel aspects of virus–host interaction. Virology 387(2), 245–249 (2009).
   PubMed Web of Science ®Google Scholar
• Lee AM, Rojek JM, Gundersen A et al. Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers. Virology 372(1), 107–117 (2008).
   PubMedGoogle Scholar
• Wells JA. Hormone mimicry. Science 273(5274), 449–450 (1996).
   PubMedGoogle Scholar
• Wells JA, de Vos AM. Hematopoietic receptor complexes. Annu. Rev. Biochem. 65, 609–634 (1996).
   PubMed Web of Science ®Google Scholar
• Livnah O, Stura EA, Johnson DL et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 273(5274), 464–471 (1996).
   PubMed Web of Science ®Google Scholar
• Wrighton NC, Farrell FX, Chang R et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273(5274), 458–464 (1996).
   PubMed Web of Science ®Google Scholar
• Boger DL, Desharnais J, Capps K. Solution-phase combinatorial libraries: modulating cellular signaling by targeting protein–protein or protein–DNA interactions. Angew. Chem. Int. Ed. Engl. 42(35), 4138–4176 (2003).
   PubMed Web of Science ®Google Scholar
• Boger DL, Ducray P, Chai W, Jiang W, Goldberg J. Higher order iminodiacetic acid libraries for probing protein–protein interactions. Bioorg. Med. Chem. Lett. 8(17), 2339–2344 (1998).
   PubMedGoogle Scholar
• Bolken TC, Laquerre S, Zhang Y et al. Identification and characterization of potent small-molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res. 69(2), 86–97 (2006).
   PubMed Web of Science ®Google Scholar
• Lee AM, Rojek JM, Spiropoulou CF et al. Unique small-molecule entry inhibitors of hemorrhagic fever arenaviruses. J. Biol. Chem. 283(27), 18734–18742 (2008).
   PubMed Web of Science ®Google Scholar
• Larson RA, Dai D, Hosack VT et al. Identification of a broad-spectrum arenavirus entry inhibitor. J. Virol. 82(21), 10768–10775 (2008).
   PubMed Web of Science ®Google Scholar
• York J, Dai D, Amberg SM, Nunberg JH. pH-induced activation of arenavirus membrane fusion is antagonized by small-molecule inhibitors. J. Virol. 82(21), 10932–10939 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas CJ, Casquilho-Gray HE, York J et al. A specific interaction of small-molecule entry inhibitors with the envelope glycoprotein complex of the Junín hemorrhagic fever arenavirus. J. Biol. Chem. 286(8), 6192–6200 (2011).
   PubMed Web of Science ®Google Scholar
• York J, Nunberg JH. Intersubunit interactions modulate pH-induced activation of membrane fusion by the Junin virus envelope glycoprotein GPC. J. Virol. 83(9), 4121–4126 (2009).
   PubMed Web of Science ®Google Scholar
• Cashman KA, Smith MA, Twenhafel NA et al. Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antiviral Res. 90(1), 70–79 (2011).
   PubMed Web of Science ®Google Scholar
• Parker WB. Metabolism and antiviral activity of ribavirin. Virus Res. 107(2), 165–171 (2005).
   PubMed Web of Science ®Google Scholar
• McCormick JB, King IJ, Webb PA et al. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 314(1), 20–26 (1986).
   PubMed Web of Science ®Google Scholar
• Kilgore PE, Peters CJ, Mills JN et al. Prospects for the control of Bolivian hemorrhagic fever. Emerging Infect. Dis. 1(3), 97–100 (1995).
   PubMed Web of Science ®Google Scholar
• Weissenbacher MC, Laguens RP, Coto CE. Argentine hemorrhagic fever. Curr. Top. Microbiol. Immunol. 134, 79–116 (1987).
   PubMedGoogle Scholar
• Ruiz-Jarabo CM, Ly C, Domingo E, de la Torre JC. Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 308(1), 37–47 (2003).
   PubMed Web of Science ®Google Scholar
• Moreno H, Gallego I, Sevilla N, de la Torre JC, Domingo E, Martín V. Ribavirin can be mutagenic for arenaviruses. J. Virol. 85(14), 7246–7255 (2011).
   PubMed Web of Science ®Google Scholar
• Andrei G, De Clercq E. Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 22(1), 45–75 (1993).
   PubMed Web of Science ®Google Scholar
• Andrei G, De Clercq E. Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro. Antiviral Res. 14(4–5), 287–299 (1990).
   PubMed Web of Science ®Google Scholar
• Candurra NA, Maskin L, Damonte EB. Inhibition of arenavirus multiplication in vitro by phenotiazines. Antiviral Res. 31(3), 149–158 (1996).
   PubMed Web of Science ®Google Scholar
• Wachsman MB, López EM, Ramirez JA, Galagovsky LR, Coto CE. Antiviral effect of brassinosteroids against herpes virus and arenaviruses. Antivir. Chem. Chemother. 11(1), 71–77 (2000).
   PubMed Web of Science ®Google Scholar
• García CC, Candurra NA, Damonte EB. Antiviral and virucidal activities against arenaviruses of zinc-finger active compounds. Antivir. Chem. Chemother. 11(3), 231–237 (2000).
   PubMed Web of Science ®Google Scholar
• García CC, Djavani M, Topisirovic I, Borden KL, Salvato MS, Damonte EB. Arenavirus Z protein as an antiviral target: virus inactivation and protein oligomerization by zinc finger-reactive compounds. J. Gen. Virol. 87(Pt 5), 1217–1228 (2006).
   PubMed Web of Science ®Google Scholar
• García CC, Topisirovic I, Djavani M, Borden KL, Damonte EB, Salvato MS. An antiviral disulfide compound blocks interaction between arenavirus Z protein and cellular promyelocytic leukemia protein. Biochem. Biophys. Res. Commun. 393(4), 625–630 (2010).
   PubMed Web of Science ®Google Scholar
• Furuta Y, Takahashi K, Shiraki K et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 82(3), 95–102 (2009).
   PubMed Web of Science ®Google Scholar
• Mendenhall M, Russell A, Juelich T et al. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob. Agents Chemother. 55(2), 782–787 (2011).
   PubMed Web of Science ®Google Scholar
• Gowen BB, Wong MH, Jung KH et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother. 51(9), 3168–3176 (2007).
   PubMed Web of Science ®Google Scholar
• Gowen BB, Smee DF, Wong MH et al. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS ONE 3(11), e3725 (2008).
   PubMed Web of Science ®Google Scholar
• Mendenhall M, Russell A, Smee DF et al. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever. PLoS Negl. Trop. Dis. 5(10), e1342 (2011).
   PubMed Web of Science ®Google Scholar
• Neuman BW, Bederka LH, Stein DA, Ting JP, Moulton HM, Buchmeier MJ. Development of peptide-conjugated morpholino oligomers as pan-arenavirus inhibitors. Antimicrob. Agents Chemother. 55(10), 4631–4638 (2011).
   PubMedGoogle Scholar
• Sepúlveda CS, García CC, Fascio ML et al. Inhibition of Junin virus RNA synthesis by an antiviral acridone derivative. Antiviral Res. 93(1), 16–22 (2012).
   PubMed Web of Science ®Google Scholar
• Samuel CE. Antiviral actions of interferons. Clin. Microbiol. Rev. 14(4), 778–809, table of contents (2001).
   PubMed Web of Science ®Google Scholar
• Bartholdy C, Christensen JP, Wodarz D, Thomsen AR. Persistent virus infection despite chronic cytotoxic T-lymphocyte activation in gamma interferon-deficient mice infected with lymphocytic choriomeningitis virus. J. Virol. 74(22), 10304–10311 (2000).
   PubMed Web of Science ®Google Scholar
• Huang S, Hendriks W, Althage A et al. Immune response in mice that lack the interferon-gamma receptor. Science 259(5102), 1742–1745 (1993).
   PubMed Web of Science ®Google Scholar
• Baize S, Kaplon J, Faure C, Pannetier D, Georges-Courbot MC, Deubel V. Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J. Immunol. 172(5), 2861–2869 (2004).
   PubMed Web of Science ®Google Scholar
• Mahanty S, Hutchinson K, Agarwal S, McRae M, Rollin PE, Pulendran B. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol. 170(6), 2797–2801 (2003).
   PubMed Web of Science ®Google Scholar
• Groseth A, Hoenen T, Weber M et al. Tacaribe virus but not junin virus infection induces cytokine release from primary human monocytes and macrophages. PLoS Negl. Trop. Dis. 5(5), e1137 (2011).
   Google Scholar
• Borrow P, Martínez-Sobrido L, de la Torre JC. Inhibition of the type I interferon antiviral response during arenavirus infection. Viruses 2(11), 2443–2480 (2010).
   PubMedGoogle Scholar
• Martínez-Sobrido L, Zúñiga EI, Rosario D, García-Sastre A, de la Torre JC. Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 80(18), 9192–9199 (2006).
   PubMed Web of Science ®Google Scholar
• Martínez-Sobrido L, Giannakas P, Cubitt B, García-Sastre A, de la Torre JC. Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J. Virol. 81(22), 12696–12703 (2007).
   PubMed Web of Science ®Google Scholar
• Martínez-Sobrido L, Emonet S, Giannakas P, Cubitt B, García-Sastre A, de la Torre JC. Identification of amino acid residues critical for the anti-interferon activity of the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 83(21), 11330–11340 (2009).
   PubMed Web of Science ®Google Scholar
• Qi X, Lan S, Wang W et al. Cap binding and immune evasion revealed by Lassa nucleoprotein structure. Nature 468(7325), 779–783 (2010).
   PubMed Web of Science ®Google Scholar
• Hastie KM, Kimberlin CR, Zandonatti MA, MacRae IJ, Saphire EO. Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3´ to 5´ exonuclease activity essential for immune suppression. Proc. Natl Acad. Sci. USA 108(6), 2396–2401 (2011).
   PubMed Web of Science ®Google Scholar
• Gowen BB, Barnard DL, Smee DF et al. Interferon alfacon-1 protects hamsters from lethal pichinde virus infection. Antimicrob. Agents Chemother. 49(6), 2378–2386 (2005).
   PubMed Web of Science ®Google Scholar
• Gowen BB, Smee DF, Wong MH et al. Combinatorial ribavirin and interferon alfacon-1 therapy of acute arenaviral disease in hamsters. Antivir. Chem. Chemother. 17(4), 175–183 (2006).
   PubMedGoogle Scholar
• Gowen BB, Ennis J, Russell A, Sefing EJ, Wong MH, Turner J. Use of recombinant adenovirus vectored consensus IFN-α to avert severe arenavirus infection. PLoS ONE 6(10), e26072 (2011).
   PubMed Web of Science ®Google Scholar
• Hallenberger S, Bosch V, Angliker H, Shaw E, Klenk HD, Garten W. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 360(6402), 358–361 (1992).
   PubMed Web of Science ®Google Scholar
• Walker JA, Molloy SS, Thomas G et al. Sequence specificity of furin, a proprotein-processing endoprotease, for the hemagglutinin of a virulent avian influenza virus. J. Virol. 68(2), 1213–1218 (1994).
   PubMedGoogle Scholar
• Horimoto T, Kawaoka Y. The hemagglutinin cleavability of a virulent avian influenza virus by subtilisin-like endoproteases is influenced by the amino acid immediately downstream of the cleavage site. Virology 210(2), 466–470 (1995).
   PubMedGoogle Scholar
• Vincent MJ, Sanchez AJ, Erickson BR et al. Crimean–Congo hemorrhagic fever virus glycoprotein proteolytic processing by subtilase SKI-1. J. Virol. 77(16), 8640–8649 (2003).
   PubMedGoogle Scholar
• Kunz S, Edelmann KH, de la Torre JC, Gorney R, Oldstone MB. Mechanisms for lymphocytic choriomeningitis virus glycoprotein cleavage, transport, and incorporation into virions. Virology 314(1), 168–178 (2003).
   PubMed Web of Science ®Google Scholar
• Touré BB, Munzer JS, Basak A et al. Biosynthesis and enzymatic characterization of human SKI-1/S1P and the processing of its inhibitory prosegment. J. Biol. Chem. 275(4), 2349–2358 (2000).
   PubMed Web of Science ®Google Scholar
• Sakai J, Rawson RB, Espenshade PJ et al. Molecular identification of the sterol-regulated luminal protease that cleaves SREBPs and controls lipid composition of animal cells. Mol. Cell 2(4), 505–514 (1998).
   PubMed Web of Science ®Google Scholar
• Espenshade PJ, Cheng D, Goldstein JL, Brown MS. Autocatalytic processing of site-1 protease removes propeptide and permits cleavage of sterol regulatory element-binding proteins. J. Biol. Chem. 274(32), 22795–22804 (1999).
   PubMedGoogle Scholar
• Ye J, Rawson RB, Komuro R et al. ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol. Cell 6(6), 1355–1364 (2000).
   PubMed Web of Science ®Google Scholar
• Raggo C, Rapin N, Stirling J et al. Luman, the cellular counterpart of herpes simplex virus VP16, is processed by regulated intramembrane proteolysis. Mol. Cell. Biol. 22(16), 5639–5649 (2002).
   PubMedGoogle Scholar
• Marschner K, Kollmann K, Schweizer M, Braulke T, Pohl S. A key enzyme in the biogenesis of lysosomes is a protease that regulates cholesterol metabolism. Science 333(6038), 87–90 (2011).
   PubMedGoogle Scholar
• Pasquato A, Pullikotil P, Asselin MC et al. The proprotein convertase SKI-1/S1P. In vitro analysis of Lassa virus glycoprotein-derived substrates and ex vivo validation of irreversible peptide inhibitors. J. Biol. Chem. 281(33), 23471–23481 (2006).
   PubMedGoogle Scholar
• Pasquato A, Burri DJ, Traba EG, Hanna-El-Daher L, Seidah NG, Kunz S. Arenavirus envelope glycoproteins mimic autoprocessing sites of the cellular proprotein convertase subtilisin kexin isozyme-1/site-1 protease. Virology 417(1), 18–26 (2011).
   PubMedGoogle Scholar
• Mohottalage D, Goto N, Basak A. Subtilisin kexin isozyme-1 (SKI-1): production, purification, inhibitor design and biochemical applications. Adv. Exp. Med. Biol. 611, 83–84 (2009).
   PubMedGoogle Scholar
• Rojek JM, Pasqual G, Sanchez AB, Nguyen NT, de la Torre JC, Kunz S. Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel antiviral strategy against arenaviruses. J. Virol. 84(1), 573–584 (2010).
   PubMed Web of Science ®Google Scholar
• Maisa A, Ströher U, Klenk HD, Garten W, Strecker T. Inhibition of Lassa virus glycoprotein cleavage and multicycle replication by site 1 protease-adapted alpha(1)-antitrypsin variants. PLoS Negl. Trop. Dis. 3(6), e446 (2009).
   Google Scholar
• Hay BA, Abrams B, Zumbrunn AY et al. Aminopyrrolidineamide inhibitors of site-1 protease. Bioorg. Med. Chem. Lett. 17(16), 4411–4414 (2007).
   PubMed Web of Science ®Google Scholar
• Hawkins JL, Robbins MD, Warren LC et al. Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals. J. Pharmacol. Exp. Ther. 326(3), 801–808 (2008).
   PubMed Web of Science ®Google Scholar
• Pasquato A, Rochat C, Burri DJ, Pasqual G, de la Torre JC, Kunz S. Evaluation of the anti-arenaviral activity of the subtilisin kexin isozyme-1/site-1 protease inhibitor PF-429242. Virology 423(1), 14–22 (2012).
   PubMed Web of Science ®Google Scholar
• Urata S, Yun N, Pasquato A, Paessler S, Kunz S, de la Torre JC. Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. J. Virol. 85(2), 795–803 (2011).
   PubMedGoogle Scholar
• Oldstone MB, Buchmeier MJ. Restricted expression of viral glycoprotein in cells of persistently infected mice. Nature 300(5890), 360–362 (1982).
   PubMedGoogle Scholar
• Olmstead AD, Knecht W, Lazarov I, Dixit SB, Jean F. Human subtilase SKI-1/S1P is a master regulator of the HCV lifecycle and a potential host cell target for developing indirect-acting antiviral agents. PLoS Pathog. 8(1), e1002468 (2012).
   PubMed Web of Science ®Google Scholar
• Burri DJ, Pasqual G, Rochat C, Seidah NG, Pasquato A, Kunz S. Molecular characterization of the processing of arenavirus envelope glycoprotein precursors by subtilisin kexin isozyme-1/site-1 protease. J. Virol. 86(9), 4935–4946 (2012).
   PubMedGoogle Scholar
• Ortiz-Riaño E, Cheng BY, de la Torre JC, Martínez-Sobrido L. Self-association of lymphocytic choriomeningitis virus nucleoprotein is mediated by its N-terminal region and is not required for its anti-interferon function. J. Virol. 86(6), 3307–3317 (2012).
   PubMedGoogle Scholar
• Ortiz-Riaño E, Cheng BY, de la Torre JC, Martínez-Sobrido L. The C-terminal region of lymphocytic choriomeningitis virus nucleoprotein contains distinct and segregable functional domains involved in NP–Z interaction and counteraction of the type I interferon response. J. Virol. 85(24), 13038–13048 (2011).
   PubMedGoogle Scholar
• Perez M, Greenwald DL, de la Torre JC. Myristoylation of the RING finger Z protein is essential for arenavirus budding. J. Virol. 78(20), 11443–11448 (2004).
   PubMed Web of Science ®Google Scholar
• Strecker T, Maisa A, Daffis S, Eichler R, Lenz O, Garten W. The role of myristoylation in the membrane association of the Lassa virus matrix protein Z. Virol. J. 3, 93 (2006).
   PubMed Web of Science ®Google Scholar
• Cordo SM, Candurra NA, Damonte EB. Myristic acid analogs are inhibitors of Junin virus replication. Microbes Infect. 1(8), 609–614 (1999).
   PubMed Web of Science ®Google Scholar
• Saunders AA, Ting JP, Meisner J et al. Mapping the landscape of the lymphocytic choriomeningitis virus stable signal peptide reveals novel functional domains. J. Virol. 81(11), 5649–5657 (2007).
   PubMedGoogle Scholar
• Urata S, Ngo N, de la Torre JC. The PI3K/Akt pathway contributes to arenavirus budding. J. Virol. 86(8), 4578–4585 (2012).
   PubMedGoogle Scholar
• Artuso MC, Ellenberg PC, Scolaro LA, Damonte EB, García CC. Inhibition of Junín virus replication by small interfering RNAs. Antiviral Res. 84(1), 31–37 (2009).
   PubMed Web of Science ®Google Scholar
• Sánchez AB, Perez M, Cornu T, de la Torre JC. RNA interference-mediated virus clearance from cells both acutely and chronically infected with the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 79(17), 11071–11081 (2005).
   PubMedGoogle Scholar
• Capul AA, de la Torre JC. A cell-based luciferase assay amenable to high-throughput screening of inhibitors of arenavirus budding. Virology 382(1), 107–114 (2008).
   PubMed Web of Science ®Google Scholar